Mavorixafor

Overview

Mavorixafor is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL518924).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Mavorixafor expires 11 Dec 2038 and exclusivity 26 Apr 2031. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine

Canonical SMILES

C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3

InChIKey

WVLHHLRVNDMIAR-IBGZPJMESA-N